|
|
Article: Collegium Pharmaceutical to Advance its Allergic Rhinitis Product into Phase III Trials.
- Article from:
- Business Wire
- Article date:
- December 17, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CUMBERLAND, R.I. -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it plans to proceed with its Phase III clinical program to evaluate COL 118, its novel modified release combination antihistamine for the treatment of allergic rhinitis. This is following a meeting with the U.S. Food and Drug Administration (FDA). Collegium submitted its proposed pivotal Phase III clinical protocol to the FDA for its review and comment. After receiving positive feedback and reconfirming the basis of approval requirements, Collegium will continue developing the product. COL 118 is an orally administered, modified release formulation that combines a ...
Related newspaper, magazine, and journal articles:
|